ICH S7B Non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals - Scientific guideline

This guidance describes non-clinical testing strategy for assessing the potential of a test substance to delay ventricular repolarization.
HumanScientific guidelines

The QT interval of the electrocardiogram (ECG) is a measure of the duration of ventricular depolarization and repolarization. QT interval prolongation can be caused by certain medicines. When ventricular repolarization is delayed and the QT interval is prolonged, there is an increased risk of ventricular tachyarrhythmia, including torsade de pointes, particularly when combined with other risk factors (e.g., hypokalaemia, structural heart disease, bradycardia). Thus, medicines are tested for their potential proarrhythmic effects at various stages of drug development, following this ICH guidance document which includes information concerning non-clinical assays and integrated risk assessment principles to be applied.

Please read in conjunction with the dedicated question and answer document on ICH guideline E14/S7B

Keywords: Delayed ventricular repolarization, QT interval prolongation, non-clinical, risk assessment, electrophysiology studies

Current version

Share this page